59
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Exosomes: key players in cancer and potential therapeutic strategy

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Exosomes are extracellular vesicles secreted by most eukaryotic cells and participate in intercellular communication. The components of exosomes, including proteins, DNA, mRNA, microRNA, long noncoding RNA, circular RNA, etc., which play a crucial role in regulating tumor growth, metastasis, and angiogenesis in the process of cancer development, and can be used as a prognostic marker and/or grading basis for tumor patients. Hereby, we mainly summarized as followed: the role of exosome contents in cancer, focusing on proteins and noncoding RNA; the interaction between exosomes and tumor microenvironment; the mechanisms that epithelial-mesenchymal transition, invasion and migration of tumor affected by exosomes; and tumor suppression strategies based on exosomes. Finally, the application potential of exosomes in clinical tumor diagnosis and therapy is prospected, which providing theoretical supports for using exosomes to serve precise tumor treatment in the clinic.

          Related collections

          Most cited references101

          • Record: found
          • Abstract: found
          • Article: not found

          The HSP90 chaperone machinery

          The heat shock protein 90 (HSP90) chaperone machinery is a key regulator of proteostasis. Recent progress has shed light on the interactions of HSP90 with its clients and co-chaperones, and on their functional implications. This opens up new avenues for the development of drugs that target HSP90, which could be valuable for the treatment of cancers and protein-misfolding diseases.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Using exosomes, naturally-equipped nanocarriers, for drug delivery.

            Exosomes offer distinct advantages that uniquely position them as highly effective drug carriers. Comprised of cellular membranes with multiple adhesive proteins on their surface, exosomes are known to specialize in cell-cell communications and provide an exclusive approach for the delivery of various therapeutic agents to target cells. In addition, exosomes can be amended through their parental cells to express a targeting moiety on their surface, or supplemented with desired biological activity. Development and validation of exosome-based drug delivery systems are the focus of this review. Different techniques of exosome isolation, characterization, drug loading, and applications in experimental disease models and clinic are discussed. Exosome-based drug formulations may be applied to a wide variety of disorders such as cancer, various infectious, cardiovascular, and neurodegenerative disorders. Overall, exosomes combine benefits of both synthetic nanocarriers and cell-mediated drug delivery systems while avoiding their limitations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis

              Transforming growth factor β (TGF-β) is a secreted cytokine that regulates cell proliferation, migration, and the differentiation of a plethora of different cell types. Consistent with these findings, TGF-β plays a key role in controlling embryogenic development, inflammation, and tissue repair, as well as in maintaining adult tissue homeostasis. TGF-β elicits a broad range of context-dependent cellular responses, and consequently, alterations in TGF-β signaling have been implicated in many diseases, including cancer. During the early stages of tumorigenesis, TGF-β acts as a tumor suppressor by inducing cytostasis and the apoptosis of normal and premalignant cells. However, at later stages, when cancer cells have acquired oncogenic mutations and/or have lost tumor suppressor gene function, cells are resistant to TGF-β-induced growth arrest, and TGF-β functions as a tumor promotor by stimulating tumor cells to undergo the so-called epithelial-mesenchymal transition (EMT). The latter leads to metastasis and chemotherapy resistance. TGF-β further supports cancer growth and progression by activating tumor angiogenesis and cancer-associated fibroblasts and enabling the tumor to evade inhibitory immune responses. In this review, we will consider the role of TGF-β signaling in cell cycle arrest, apoptosis, EMT and cancer cell metastasis. In particular, we will highlight recent insights into the multistep and dynamically controlled process of TGF-β-induced EMT and the functions of miRNAs and long noncoding RNAs in this process. Finally, we will discuss how these new mechanistic insights might be exploited to develop novel therapeutic interventions.
                Bookmark

                Author and article information

                Contributors
                20193068@njucm.edu.cn
                jiangyiqun@hunnu.edu.cn
                Journal
                Signal Transduct Target Ther
                Signal Transduct Target Ther
                Signal Transduction and Targeted Therapy
                Nature Publishing Group UK (London )
                2095-9907
                2059-3635
                5 August 2020
                5 August 2020
                2020
                : 5
                : 145
                Affiliations
                [1 ]GRID grid.411427.5, ISNI 0000 0001 0089 3695, The Key Laboratory of Model Animal and Stem Cell Biology in Hunan Province, Hunan Normal University, ; Changsha, 410013 Hunan China
                [2 ]GRID grid.411427.5, ISNI 0000 0001 0089 3695, School of Medicine, , Hunan Normal University, ; Changsha, 410013 Hunan China
                [3 ]GRID grid.410570.7, ISNI 0000 0004 1760 6682, Center for Joint Surgery, Southwest Hospital, , Army Medical University (Third Military Medical University), ; Chongqing, 400038 China
                [4 ]GRID grid.216417.7, ISNI 0000 0001 0379 7164, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Department of Pathology, Xiangya Hospital, School of Basic Medicine, , Central South University, ; Changsha, 410078 Hunan China
                [5 ]GRID grid.410745.3, ISNI 0000 0004 1765 1045, School of Medicine & Holistic Integrative Medicine, , Nanjing University of Chinese Medicine, ; Nanjing, 210013 Jiangsu China
                Author information
                http://orcid.org/0000-0003-2354-5321
                Article
                261
                10.1038/s41392-020-00261-0
                7406508
                32759948
                e31c5839-1d53-43bf-85db-fbb372bc8396
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 17 May 2020
                : 28 June 2020
                : 17 July 2020
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100001809, National Natural Science Foundation of China (National Science Foundation of China);
                Award ID: 81802785
                Award ID: 81802785
                Award ID: 81802785
                Award ID: 81802785
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100004735, Natural Science Foundation of Hunan Province (Hunan Provincial Natural Science Foundation);
                Award ID: 2020JJ5382
                Award ID: 2020JJ5381
                Award Recipient :
                Categories
                Review Article
                Custom metadata
                © The Author(s) 2020

                molecular medicine,cancer microenvironment,cancer stem cells,tumour immunology,tumour biomarkers

                Comments

                Comment on this article